Qihan Biotech announced its inclusion in China’s 2026 Future Unicorn Top 100 on April 28, 2026. The list was announced at the 10th All Blossom Conference in Hangzhou on April 23.
At the same event, Qihan was included in the Hangzhou quasi-unicorn list for the seventh consecutive year. Qihan has been based in Hangzhou since its founding in 2017.
Qihan Biotech develops cell and organ therapies by combining genome engineering and transplantation immunology. Its research includes allogeneic cell therapies, in vivo delivery and xenotransplantation.
Browse all news